Octreotide
 | |
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Intramuscular, intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 100%; I.M: 60% to 63% of subcutaneous dose |
| Protein binding | 65% |
| Metabolism | Hepatic |
| Elimination half-life | 1.7-1.9 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C49H66N10O10S2 |
| Molar mass | 1019.24 g/mol |
|
WikiDoc Resources for Octreotide |
|
Articles |
|---|
|
Most recent articles on Octreotide |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Octreotide at Clinical Trials.gov Clinical Trials on Octreotide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Octreotide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Octreotide Discussion groups on Octreotide Patient Handouts on Octreotide Directions to Hospitals Treating Octreotide Risk calculators and risk factors for Octreotide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Octreotide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Octreotide (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.
Effects
Somatostatin has numerous physiological effects:
- It inhibits secretion of many hormones, such as gastrin, cholecystokinin, glucagon, growth hormone, insulin, secretin, pancreatic polypeptide, TSH, and vasoactive intestinal peptide.
- It reduces secretion of fluids by the intestine and pancreas.
- It reduces gastrointestinal motility and inhibits contraction of the gallbladder.
- It inhibits the secretion of certain hormones from the anterior pituitary.
Uses
The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, the treatment of diarrhea and flushing episodes associated with carcinoid syndrome, and treatment of diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas).
Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea overdose.
Octreotide has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.
In patients with suspected esophageal varices, octreotide can be given to help decrease bleeding.
Octreotide has been investigated for patients with pain from chronic pancreatitis.[1]
References
- Katzung, Bertram G. (ed.), ed. (2004). Basic and Clinical Pharmacology. Stamford, Conn: Lange Medical Books/McGraw Hill. ISBN 0-07-141092-9.
External links
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Extra text: editors list
- Hormonal agents
- Endocrinology